Study Confirms PFS Benefit of Second-line Everolimus for mRCC

Share this content:
Progression-free survival benefit of second-line everolimus after first-line sunitinib or other anti-vascular endothelial growth factor therapies.
Progression-free survival benefit of second-line everolimus after first-line sunitinib or other anti-vascular endothelial growth factor therapies.

The progression-free survival benefit of second-line everolimus after first-line sunitinib or other anti-vascular endothelial growth factor (VEGF) therapies in patients with metastatic renal cell carcinoma (mRCC) was confirmed, according to results of the RECORD-4 trial published in the journal Annals of Oncology has shown.1

Because the RECORD-1 trial demonstrated clinical benefit of everolimus in patients with mRCC previously treated with sunitinib, sorafenib, or both, as well as prior treatment with cytokines, bevacizumab, and chemotherapy, researchers sought to evaluate everolimus in a purely second-line setting.

For the study, researchers enrolled 134 patients with clear cell mRCC who had received first-line therapy with sunitinib, other anti-VEGF agents, or cytokines. Of those, 58 patients had received sunitinib, 23 received sorafenib, 16 received bevacizumab, 13 pazopanib, and 14 had received cytokines.

Fifty-two percent of patients were of favorable Memorial Sloan Kettering Cancer Center (MSKCC) risk while 37% were of intermediate MSKCC risk. All patients received everolimus 10 mg orally daily until disease progression or unacceptable toxicity.

Results showed that the overall median progression-free survival was 7.8 months (95% CI, 3.7 - 11.3). For patients who had received previous sunitinib, the median progression-free survival was 5.7 months (95% CI, 3.7 - 11.3), vs 7.8 months (95% CI, 5.7 - 11.0) among patients who had received other previous anti-VEGF therapy, and 12.9 months (95% CI, 2.6 - not estimable) with previous cytokines.

Median overall survival was 23.8 months (95% CI, 13.7 - not estimable), 17.2 months (95% CI, 11.9 - not estimable), and not estimable (95% CI, 15.9 - not estimable), respectively.

RELATED: Nivolumab Approved for Metastatic Renal Cell Carcinoma

In terms of response, 67% of all patients achieved stable disease as their best response.

A total of 56% of patients experienced a grade 3 or adverse event. Researchers found that the safety profile of everolimus was consistent with previous findings.

Reference

  1. Motzer RJ, Alyasova A, Ye D, et al. Phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4) [published online ahead of print December 17, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv612.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters